Prometheus Biosciences Accounts Payable

Prometheus Biosciences (RXDX) currently reports a accounts payable of $1.2M as of March 2023. That compares with $1.8M in the prior-year period — down 35.9% year over year. Use the charts on this page to explore Prometheus Biosciences's accounts payable history and peer comparisons.

Prometheus Biosciences's accounts payable decreased from $1.8M to $1.2M — a 35.9% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Prometheus Biosciences reported $1.2M in accounts payable as of March 2023. That compares with $1.8M in the prior-year period — down 35.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Prometheus Biosciences, and consider following RXDX for alerts when major investors trade the stock.

Prometheus Biosciences is classified in the Healthcare sector. On accounts payable, it currently shows $1.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RXDX with unrelated industries.